Evidence map›Paper›PMID 40333746›Full record

ArticlePloS one2025

Performance of BIOCREDIT Pf/Pv lactate dehydrogenase-based malaria rapid diagnostic test among pregnant women with suspected malaria infection in Bahir Dar City Administration, northwest Ethiopia.

Banchamlak Tegegne, Endalkachew Nibret, Abaineh Munshea, Mekonnen Teferi, Mulat Yimer, Getaneh Alemu, Delenasaw Yewhalaw, Dylan R Pillai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Banchamlak TegegneBiology Department, Science College, Bahir Dar University, Bahir Dar, Ethiopia.ORCID https://orcid.org/0000-0002-9916-3162
Endalkachew NibretBiology Department, Science College, Bahir Dar University, Bahir Dar, Ethiopia.
Abaineh MunsheaBiology Department, Science College, Bahir Dar University, Bahir Dar, Ethiopia.ORCID https://orcid.org/0000-0002-1469-2189
Mekonnen TeferiArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Mulat YimerDepartment of Medical Laboratory Science, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.
Getaneh AlemuDepartment of Medical Laboratory Science, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.
Delenasaw YewhalawSchool of Medical Laboratory Sciences, Faculty of Health Sciences, Jimma University, Jimma, Ethiopia.
Dylan R PillaiPathology and Laboratory Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalaria during pregnancy is a common public health problem in sub-Saharan Africa. It poses a double burden as it affects the health of mothers, their fetuses and neonates. Moreover, due to malaria parasites sequestration in the placenta, microscopy might miss infections. Hence, rapid diagnostic tests (RDTs) are good alternatives for diagnosing malaria in pregnancy even at health facilities or periphery or lower-level healthcare facilities (e.g., health posts). However, performance of RDTs should be closely monitored as their sensitivity and specificity are affected by many factors.

methodsA health facility-based cross-sectional study was conducted among 302 pregnant women with suspected malaria infection to evaluate the performance of the newly introduced BIOCREDIT Pf/Pv plasmodial lactate dehydrogenase (pLDH) RDT. Venous blood samples were collected from all eligible pregnant women and tested for Plasmodium infection using BIOCREDIT Pf/Pv and CareStart™ Pf/Pv RDTs, microscopy and polymerase chain reaction (PCR) following standard protocols. The performance of BIOCREDIT Pf/Pv was evaluated using the following parameters: sensitivity, specificity, positive and negative predictive values and kappa-value. These parameters were calculated using online SISA software.

resultsOf the 302 pregnant women with complete data, 166 (55.0%), 180 (59.6%), 191 (63.2%) and 207 (68.5%) tested positive by CareStart™ Pf/Pv, BIOCREDIT Pf/Pv, microscopy and PCR, respectively. The sensitivity of BIOCREDIT Pf/Pv in detecting P. falciparum was 89.4%, 75.4% and 55.6% as compared to CareStart™ Pf/Pv, microscopy and PCR tests, respectively, while the sensitivity for P. vivax was 81.8%, 84.3% and 86.7%, respectively. The specificity of BIOCREDIT Pf/Pv was > 90% when compared to all the three diagnostic tests. When considering PCR as a reference test, BIOCREDIT Pf/Pv was more sensitive (55.6%) than CareStart™ Pf/Pv (37.6%) for detecting P. falciparum but had similar sensitivity (86.7%) in detecting P. vivax.

conclusionsBIOCREDIT Pf/Pv performed better for the diagnosis of P. falciparum infection in pregnant women than the previously in-use CareStart™ Pf/Pv. We recommend using the BIOCREDIT Pf/Pv RDT in Ethiopia for the diagnosis of both species given the high prevalence and widespread nature of the hrp2/3 gene deletion in the country.

Indexed as

Diagnostic Tests, RoutineL-Lactate DehydrogenaseMalariaMalaria, FalciparumMalaria, VivaxPlasmodium falciparumPlasmodium vivaxPregnancy Complications, ParasiticAdolescentAdultCross-Sectional StudiesEthiopiaFemaleHumansPregnancyRapid Diagnostic TestsL-Lactate Dehydrogenase

Identifiers

PMID40333746
PMCPMC12057965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.